Bristol Late-Stage Pipeline Reflects Success Of In-House Development
Executive Summary
Bristol-Myers Squibb's late-stage pipeline will include 80% internally developed agents, with three of those compounds moving into Phase III
You may also be interested in...
Bristol R&D Success Shows Link Between Licensing And First-Cycle Approval
Bristol-Myers Squibb's heavy reliance on in-licensing products in the first half of the decade appears to have paid off with a high number of new molecular entity submissions and a relatively strong first-cycle approval record
Bristol R&D Success Shows Link Between Licensing And First-Cycle Approval
Bristol-Myers Squibb's heavy reliance on in-licensing products in the first half of the decade appears to have paid off with a high number of new molecular entity submissions and a relatively strong first-cycle approval record
Bristol Baraclude Will Be Available April 8; Premium Price Planned
Bristol-Myers Squibb's Baraclude (entecavir) will be available on pharmacy shelves April 8 following FDA approval of the hepatitis B therapy